SmithKline Paxil patents
Executive Summary
FTC has opened an investigation "to determine whether SmithKline has engaged in unfair methods of competition...by preventing or impeding competition to Paxil from generic paroxetine," Apotex/Torpharm discloses in Dec. 5 court filing. The companies are in litigation over "late-listed" patents (1"The Pink Sheet" Dec. 4, p. 25)